AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Platelet basic protein

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P02775

UPID:

CXCL7_HUMAN

Alternative names:

C-X-C motif chemokine 7; Leukocyte-derived growth factor; Macrophage-derived growth factor; Small-inducible cytokine B7

Alternative UPACC:

P02775; B2R5F3; Q6IBJ8

Background:

Platelet basic protein, also known as C-X-C motif chemokine 7, plays a pivotal role in various biological processes. It is involved in DNA synthesis, mitosis, glycolysis, and the secretion of several substances including prostaglandin E2 and plasminogen activator. Its ability to act as a chemoattractant and activator for neutrophils through its forms such as NAP-2 highlights its significance in immune responses. Additionally, its derivatives, TC-1 and TC-2, exhibit antibacterial properties, showcasing its multifunctionality in host defense mechanisms.

Therapeutic significance:

Understanding the role of Platelet basic protein could open doors to potential therapeutic strategies. Its involvement in critical cellular processes and immune responses positions it as a key target for drug discovery efforts aimed at treating inflammatory conditions and infections.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.